Page 176 - Screening for Cervical Cancer: Systematic Evidence Review
P. 176
Screening for Cervical Cancer
Neg LR 0.6 0.1 0.2 0.1 0.2 0.3 0.5 0.5 0.5 0.4 0.3
Pos LR 1.6 1.6 2.3 3.3 2.5 2.9 1.7 1.3 1.4 1.7 2.1
HPV Testing as a Triage Tool Among Women with an Abnormal Pap Test for Detection of HSIL*
NPV 91.0 94.7 94.0 98.0 98.8 75.2 61.9 89.0 89.2 87.7 96.6
PPV 21.7 39.8 42.2 37.2 15.1 77.6 67.0 24.4 26.2 38.5 22.1
Prev HGSIL 14.5 29.5 24.0 15.4 6.7 54.5 54.5 20.2 20.2 27.4 12.0
Spec 60.1 40.3 62.2 71.8 64.1 72.4 58.9 34.9 43.6 51.3 59.6
False Pos. 155 80 48 59 326 45 67 270 234 598 619
True Neg 233 54 79 150 582 118 96 145 181 629 913
Sens 65.2 94.6 87.5 92.1 89.2 80.0 69.7 82.9 79.0 81.0 84.6
False Neg 23 3 5 3 7 39 59 18 22 88 32
True Pos. 43 53 35 35 58 156 136 87 83 374 176
Total N 454 190 167 247 973 358 358 520 520 1689 1740 *HPV, human papilloma virus; HSIL, high-grade squamous intraepithelial lesion.
Test Method Consensu s PCR SHARP PCR Consensu s PCR II HC II HC Consensu s PCR I HC Consensu s PCR II HC
Table 11. Author (Year) Adam et al., 1998 71 Bollen et al., 1997 66 Herrington et al., 1995 69 Hillemanns et al., 1999 72 Manos et al., 1999 68 Sigurdsson et al., 1997 67 Sun et al., 1995 73 PCR all Total all HC II
Total
74
